SYNformulas, a global probiotics company, will present its new Kijimea probiotic product targeting allergies and gastrointestinal conditions.
The range includes the heat-inactivated form of the bacterial strain B. bifidum HI-MIMBb75 which is said to provide a unique texture and high stability, which plays a key role for further processing.
David Rietbrock, Managing Director of SYNformulas, says the scientifically proven impact of the bacterial strain offers real potential for additional applications.
Irritable Bowel Syndrome (IBS), affects approximately 11% of the world's population. In independent studies, the bacterial strain MIMBb75 has been proven to be significantly effective on all symptoms of IBS such as diarrhea, abdominal pain, flatulence and constipation.
So far, the bacterial strain is exclusively used in the product Kijimea IBS and in its heat-inactivated form in Kijimea IBS PRO but through extended licensing partnerships the firm wants to give other potential partners in the food and pharmaceutical sectors the chance to use the innovation.
Royal DSM will also present at the show its range of purpose-led solutions targeting immunity and the gut.
Providing a gut health focused immunity solution to the market, the global firm will showcase its latest solution, 'V-Direct' supplement, which utilises unique coating technology.
'V-Direct' is a new supplement solution providing a combination of C and B-group vitamins in a unique coating which helps these to reach the upper and lower gut.
The firm points out that the gut is one of the key lines of defence against illness with 80% of all immune cells residing in the gut and research showing that vitamins delivered to the lower gut increase microbial diversity.
The firm will also showcase its algal-derived omega-3 – 'life’s OMEGA' – aplant-based omega-3 that delivers the health benefits of both eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Well-known for supporting brain, eye and heart health, the extended benefits of 'life’s OMEGA' include its role in immunity, sports performance, mood and sleep.
Another solution on show will be its fast-acting vitamin D product 'ampli-D'. Earlier this year, DSM received a positive EFSA opinion for the Novel Food assessment of calcidiol, also known as calcifediol, that recognised the more efficient absorption of calcidiol compared to regular vitamin D3. Once the European Commission gives its authorisation, DSM will launch the solution across Europe where it will open up opportunities to quickly tackle low vitamin D status.